Literature DB >> 19470418

Predisposing factors of actinic keratosis in a North-West German population.

Peter Hensen1, Marcel L Müller, Ramin Haschemi, Hartmut Ständer, Thomas A Luger, Cord Sunderkötter, Meinhard Schiller.   

Abstract

The growing incident rates of skin cancer and their corresponding precursor lesions, e.g. actinic keratosis (AK), among Caucasians have become an important public health problem. A multicenter case-control study was conducted to identify the risk factors of AK of a prototypical Central European population. The study population comprised a total of 331 cases and 383 controls. Using multivariate analysis we identified ten independent variables predicting the AK risk. The five most crucial were age (OR 1.11; 95% CI 1.08-1,14), gender (OR 3.92; 95% CI 2.42-6.36), history of previous skin malignancies (OR 6.47; 95% CI 3.21-13.03), pale skin phototype (OR 2.5; 95% CI 1.53-4.06), and sun exposure for occupational reasons (OR 1.72; 95% CI 1.01-2.92). Additionally, sun exposure for recreational reasons, denial of the use of sunscreens, painful sunburn episodes before the age of 20, and a familial history of skin malignancies are also significant independent correlates of AK. Our epidemiological data suggest that constitutional susceptibility and sunlight exposure are equally involved in the onset of AK. Additional prophylactic and educational efforts should focus on increasing sun protection policies and educational programs especially aimed at outdoor workers, men, fair skinned individuals and patients with a history of previous skin malignancies. These measures should be able to reduce the excessive incidence rates of AK among Caucasians in Central Europe.

Entities:  

Mesh:

Year:  2009        PMID: 19470418     DOI: 10.1684/ejd.2009.0706

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  14 in total

1.  Rational management of papulopustular rosacea with concomitant facial seborrheic dermatitis: a case report.

Authors:  Wendy L McFalda; Heather L Roebuck
Journal:  J Clin Aesthet Dermatol       Date:  2011-01

2.  Evaluation of the skin sensitization, photoirritation, and photoallergic potential of ingenol mebutate gel in healthy volunteers.

Authors:  Jonathan S Dosik; Maureen Damstra; Carol Udell; Peter Welburn
Journal:  J Clin Aesthet Dermatol       Date:  2014-04

Review 3.  [Actinic keratoses. Pathogenesis, clinical aspect and modern therapeutic options].

Authors:  T Strunk; R-M Szeimies
Journal:  Hautarzt       Date:  2014-03       Impact factor: 0.751

4.  Pharmacoeconomy of drugs used in the treatment of actinic keratoses.

Authors:  S Nisticò; V Torchia; M Gliozzi; U Bottoni; E Del Duca; C Muscoli
Journal:  Int J Immunopathol Pharmacol       Date:  2016-05-11       Impact factor: 3.219

Review 5.  Actinic keratosis: update on field therapy.

Authors:  Gary Goldenberg; Marcel Perl
Journal:  J Clin Aesthet Dermatol       Date:  2014-10

Review 6.  UV-induced skin cancer at workplace and evidence-based prevention.

Authors:  Birgitta Kütting; Hans Drexler
Journal:  Int Arch Occup Environ Health       Date:  2010-04-23       Impact factor: 3.015

Review 7.  [Actinic keratoses].

Authors:  T Hommel; R-M Szeimies
Journal:  Hautarzt       Date:  2016-11       Impact factor: 0.751

8.  Drug Intake and Actinic Keratosis: A Case-Control Study.

Authors:  Andrea Sechi; Ambra di Altobrando; Eugenio Cerciello; Elisa Maietti; Annalisa Patrizi; Francesco Savoia
Journal:  Dermatol Pract Concept       Date:  2021-04-12

9.  Clinical Features of Cutaneous Premalignant Lesions in Busan City and the Eastern Gyeongnam Province, Korea: A Retrospective Review of 1,292 Cases over 19 Years (1995~2013).

Authors:  Seung-Hwan Choi; Ki-Ho Kim; Ki-Hoon Song
Journal:  Ann Dermatol       Date:  2016-03-31       Impact factor: 1.444

Review 10.  Recommendations for managing cutaneous disorders associated with advancing age.

Authors:  Philippe Humbert; Brigitte Dréno; Jean Krutmann; Thomas Anton Luger; Raoul Triller; Sylvie Meaume; Sophie Seité
Journal:  Clin Interv Aging       Date:  2016-02-12       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.